Bertold Bar-Bouyssière

Dentons (Brussels)
Lawyer (Of Counsel)

Bertold Bär-Bouyssière is Of Counsel in Dentons’ Berlin office and a member of the Competition and Antitrust practice group. With more than 25 years of practice, Bertold is one of the leading advisors in EU and German competition law. A senior member of the “EU Brussels bubble”, Bertold combines legal skills with insights into competition policy dynamics to offer clients sustainable strategic antitrust solutions. Over the years, Bertold supported clients in a wide range of sectors, including satellite communications, aerospace and defense, life sciences, petrochemicals, automotive vehicles, air and maritime transport, tourism, consumer products, financial services, energy and life sciences. Bertold’s skills range over all areas of antitrust : merger control, the design of distribution networks, advisory, litigation and state aid. As a long-time Co-Chair of AmCham EU’s Competition Policy Committee, Bertold has contributed to submissions on most current competition policy initiatives, particularly those relating to digital policy and the EU’s geopolitical awakening. Bertold provides pro bono legal assistance to EURORDIS. With his family, Bertold has been financially sponsoring the education of two Ethiopian children on an ongoing basis since 2002.

Distinctions

Auteurs associés

Dentons (Warsaw)
Dentons (Warsaw)
Dentons (Brussels)
Dentons (Washington)
Dentons (Milan) (Studio Legale Tributario)

Articles

5039 Bulletin

Bertold Bar-Bouyssière, Alina Lacatus, Jacob Borum, Darach Connolly The EU Commission invites comments from all interested parties on commitments offered by pharmaceutical company to address the Commission’s concerns over excessive pricing (Aspen)

78

Aspen : Quick Fix But Missed Opportunity* What are commitments ? The recent effort by the Commission to settle the Aspen case suggests that commitment decisions are the preferred route to settle complex excessive pricing cases at EU-level. Previous commitment cases where high prices have been (...)

Bertold Bar-Bouyssière, Catherine Derenne Pharma and Mergers : An overview of EU and national case law

1544

Merger control in the pharmaceutical sector follows the normal pattern of merger analysis, taking account of sectoral specificities. Mergers (used here as a shortcut for all transactions subject to merger control) can involve different types of actors, e.g. manufacturers of branded drugs (’innovators’ or ’originators’), manufacturers of generic drugs, manufacturers of biosimilars, non-manufacturing inventors, universities or start-ups, different categories of wholesalers and distributors, retailers (pharmacies), hospitals, even global investment banks, and the drugs in question can be intended for human or veterinary use. There are also mergers involving manufacturers or distributors of medical equipment, other medical products, or chemicals for use in medicinal products.

Livres

Envoyer un message